Real-world outcomes of tumour necrosis factor inhibitor (TNFi) cyclers versus mechanism-of-action switchers among ulcerative colitis patients who failed first-line TNFi

Navneet Upadhyay, Amita Ketkar, Can Mert, Alexandra Wallem, Simin K. Baygani, Tariku J. Beyene, Deborah A. Fisher, Tracey Quimbo, Raven A. Perez, Michael Grabner, J. Casey Chapman

Open source

DOI
10.1186/s12876-026-04829-y
Published
2026-06-20
Container
BMC Gastroenterology
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1186/s12876-026-04829-y,
  title = {Real-world outcomes of tumour necrosis factor inhibitor (TNFi) cyclers versus mechanism-of-action switchers among ulcerative colitis patients who failed first-line TNFi},
  author = {Navneet Upadhyay and Amita Ketkar and Can Mert and Alexandra Wallem and Simin K. Baygani and Tariku J. Beyene and Deborah A. Fisher and Tracey Quimbo and Raven A. Perez and Michael Grabner and J. Casey Chapman},
  year = {2026},
  journal = {BMC Gastroenterology},
  doi = {10.1186/s12876-026-04829-y},
  url = {https://doi.org/10.1186/s12876-026-04829-y}
}

RIS

TY  - JOUR
TI  - Real-world outcomes of tumour necrosis factor inhibitor (TNFi) cyclers versus mechanism-of-action switchers among ulcerative colitis patients who failed first-line TNFi
AU  - Navneet Upadhyay
AU  - Amita Ketkar
AU  - Can Mert
AU  - Alexandra Wallem
AU  - Simin K. Baygani
AU  - Tariku J. Beyene
AU  - Deborah A. Fisher
AU  - Tracey Quimbo
AU  - Raven A. Perez
AU  - Michael Grabner
AU  - J. Casey Chapman
PY  - 2026
JO  - BMC Gastroenterology
DO  - 10.1186/s12876-026-04829-y
UR  - https://doi.org/10.1186/s12876-026-04829-y
ER  - 

APA

Upadhyay, N., Ketkar, A., Mert, C., Wallem, A., Baygani, S. K., Beyene, T. J., Fisher, D. A., Quimbo, T., Perez, R. A., Grabner, M., & Chapman, J. C. (2026). Real-world outcomes of tumour necrosis factor inhibitor (TNFi) cyclers versus mechanism-of-action switchers among ulcerative colitis patients who failed first-line TNFi. BMC Gastroenterology. https://doi.org/10.1186/s12876-026-04829-y

Source records